NO961070D0 - Acylert insulin - Google Patents

Acylert insulin

Info

Publication number
NO961070D0
NO961070D0 NO961070A NO961070A NO961070D0 NO 961070 D0 NO961070 D0 NO 961070D0 NO 961070 A NO961070 A NO 961070A NO 961070 A NO961070 A NO 961070A NO 961070 D0 NO961070 D0 NO 961070D0
Authority
NO
Norway
Prior art keywords
amino acid
acid residue
lys
present
cys
Prior art date
Application number
NO961070A
Other languages
English (en)
Other versions
NO316944B1 (no
NO961070L (no
Inventor
Svend Havelund
John Broberg Halstrom
Ib Jonassen
Asser Sloth Andersen
Jan Markussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO961070(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO961070D0 publication Critical patent/NO961070D0/no
Publication of NO961070L publication Critical patent/NO961070L/no
Publication of NO316944B1 publication Critical patent/NO316944B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19961070A 1993-09-17 1996-03-15 Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes NO316944B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
US19082994A 1994-02-02 1994-02-02
PCT/DK1994/000347 WO1995007931A1 (en) 1993-09-17 1994-09-16 Acylated insulin

Publications (3)

Publication Number Publication Date
NO961070D0 true NO961070D0 (no) 1996-03-15
NO961070L NO961070L (no) 1996-05-15
NO316944B1 NO316944B1 (no) 2004-07-05

Family

ID=26065125

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19961070A NO316944B1 (no) 1993-09-17 1996-03-15 Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes
NO2004006C NO2004006I1 (no) 1993-09-17 2004-09-27 Insulin detemir
NO2017041C NO2017041I2 (no) 1993-09-17 2017-08-01 Insulin detemir

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2004006C NO2004006I1 (no) 1993-09-17 2004-09-27 Insulin detemir
NO2017041C NO2017041I2 (no) 1993-09-17 2017-08-01 Insulin detemir

Country Status (30)

Country Link
US (1) US5750497A (no)
EP (2) EP0792290B1 (no)
JP (3) JP3014764B2 (no)
KR (1) KR100310122B1 (no)
CN (1) CN1056618C (no)
AT (1) ATE204882T1 (no)
AU (2) AU682061B2 (no)
BG (1) BG61611B1 (no)
BR (1) BR9407508A (no)
CA (1) CA2171424C (no)
CZ (1) CZ287945B6 (no)
DE (2) DE122004000035I2 (no)
DK (1) DK0792290T3 (no)
ES (1) ES2163451T3 (no)
FI (1) FI117055B (no)
FR (1) FR04C0020I2 (no)
HU (1) HU217684B (no)
IL (1) IL110977A (no)
LU (1) LU91101I2 (no)
NL (1) NL300160I2 (no)
NO (3) NO316944B1 (no)
NZ (1) NZ273285A (no)
PL (1) PL178466B1 (no)
PT (1) PT792290E (no)
RO (1) RO112873B1 (no)
RU (1) RU2164520C2 (no)
SI (1) SI0792290T1 (no)
SK (1) SK282495B6 (no)
UA (1) UA45321C2 (no)
WO (1) WO1995007931A1 (no)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE69629210T2 (de) * 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
CN1120019C (zh) * 1996-06-20 2003-09-03 诺沃挪第克公司 含NaCl的胰岛素制品
DE69731105T2 (de) * 1996-07-11 2005-11-17 Novo Nordisk A/S Verfahren zur selektiven acetylierung
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
JP3764174B2 (ja) * 1997-03-20 2006-04-05 ノボ ノルディスク アクティーゼルスカブ 肺用組成物において使用するための亜鉛非含有のインスリン結晶
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989644B (en) * 1997-10-24 2000-04-25 Lilly Co Eli Insoluble insulen compositions.
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
WO1999021573A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Fatty acid-acylated insulin analogs
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
EP1060192A2 (en) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
JP2002518408A (ja) * 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
JP2003528149A (ja) 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
WO2001085256A2 (en) * 2000-05-05 2001-11-15 Novo Nordisk A/S Critical illness neuropathy
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
CA2415425A1 (en) * 2000-07-10 2002-01-17 Btg International Limited Insulin derivatives and synthesis thereof
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
ES2271255T3 (es) * 2001-05-02 2007-04-16 Novo Nordisk A/S Preparacion de acidos biliares.
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
JP4318546B2 (ja) 2001-09-07 2009-08-26 バイオコン・リミテッド インスリンポリペプチド−オリゴマーコンジュゲートの合成方法、ならびにプロインスリンポリペプチド−オリゴマーコンジュゲートおよびその合成方法
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
PL210437B1 (pl) 2001-11-19 2012-01-31 Novo Nordisk As Sposób wytwarzania związków insuliny
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
PL210455B1 (pl) * 2002-09-25 2012-01-31 Novo Nordisk As Sposób otrzymywania acylowanych peptydów
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
ATE505323T1 (de) 2003-06-27 2011-04-15 Novo Nordisk As Behälter für medizinische flüssigkeiten mit hoher wasserdampfsperre
EP2287184A3 (en) 2003-08-05 2011-08-10 Novo Nordisk A/S Novel insulin derivatives
EP1660531A2 (en) * 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
EP2394656B1 (en) 2003-11-20 2023-12-13 Novo Nordisk A/S Pharmaceutical formulations comprising the peptide liraglutide and propylene glycol
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
WO2005061222A1 (en) 2003-12-22 2005-07-07 Novo Nordisk A/S Transparent, flexible, impermeable plastic container for storage of pharmaceutical liquids
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
EP1740154B1 (en) * 2004-03-12 2009-06-17 Biodel, Inc. Insulin compositions with improved absorption
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
ES2435522T3 (es) * 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
JP4933455B2 (ja) * 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
WO2006125763A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
WO2006125765A2 (en) * 2005-05-26 2006-11-30 Novo Nordisk A/S Acylated insulin with high purity
EP1902028A2 (en) 2005-07-04 2008-03-26 Novo Nordisk A/S Histamine h3 receptor antagonists
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
CN102660614A (zh) 2005-08-16 2012-09-12 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
KR101728868B1 (ko) * 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
EP1996223A1 (en) * 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
EP1999120B1 (en) 2006-03-28 2012-06-27 High Point Pharmaceuticals, LLC Benzothiazoles having histamine h3 receptor activity
WO2007127704A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
BRPI0715469A2 (pt) 2006-07-11 2013-03-12 Qps Llc composiÇÕes farmacÊuticas para a liberaÇço sustentada de peptÍdeos
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008145730A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
CN101677947B (zh) 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
US8575096B2 (en) 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
CA2702892C (en) * 2007-10-16 2017-02-28 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
CN101932601B (zh) 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
WO2009063072A2 (en) 2007-11-16 2009-05-22 Novo Nordisk A/S Pharmaceutical compositions containing insulin and an insulinotropic peptide
MX2010007342A (es) * 2008-01-04 2010-08-26 Biodel Inc Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
DK2910570T3 (en) 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
KR20110059602A (ko) 2008-08-07 2011-06-02 바이오콘 리미티드 인슐린 화합물의 제조방법
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP2012509879A (ja) 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー アダマンチルベンズアミド化合物
US9050370B2 (en) * 2009-01-28 2015-06-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010140148A1 (en) 2009-06-01 2010-12-09 Yeda Research And Development Co . Ltd Prodrugs containing albumin binding probe
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR080884A1 (es) 2010-04-14 2012-05-16 Sanofi Aventis Conjugados de insulina-sirna
US20130143803A1 (en) * 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
US20140315797A1 (en) * 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN103269723B (zh) 2010-12-22 2017-04-05 百深有限责任公司 用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
EP2665487A1 (en) 2011-01-20 2013-11-27 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
EP2784085A4 (en) * 2011-12-15 2015-07-08 Shanghai Hengrui Pharm Co Ltd HUMAN INSULIN ANALOG AND ACYLATED DERIVATIVITY THEREOF
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー／エス 医薬組成物
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
RS57004B1 (sr) * 2013-10-07 2018-05-31 Novo Nordisk As Novi derivat analoga insulina
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
WO2017032798A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN114478747B (zh) 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
MX2019006515A (es) 2016-12-05 2019-09-10 Nuritas Ltd Composiciones que comprenden peptido wkdeagkplvk.
EP3554534B1 (en) 2016-12-16 2021-06-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
JP2020535199A (ja) * 2017-09-29 2020-12-03 ハンミ ファーマシューティカル カンパニー リミテッド 効力が向上した持続性タンパク質結合体
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
JP2021513330A (ja) 2018-02-09 2021-05-27 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンアナログのコドン最適化前駆体遺伝子およびシグナルペプチド遺伝子
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
WO2020120479A1 (en) 2018-12-11 2020-06-18 Sanofi Peptide binder
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
EP4004028A1 (en) 2019-07-31 2022-06-01 Eli Lilly and Company Relaxin analogs and methods of using the same
IL292762A (en) 2019-12-11 2022-07-01 Novo Nordisk As Innovative insulin analogs and their use
KR20220119730A (ko) 2019-12-30 2022-08-30 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 인슐린 유도체
CA3166496A1 (en) 2019-12-30 2021-07-08 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting glp-1 compound
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
AU8091091A (en) * 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
NO316944B1 (no) 2004-07-05
SK32496A3 (en) 1996-11-06
HU9600676D0 (en) 1996-05-28
NL300160I1 (nl) 2004-12-01
EP1132404A3 (en) 2002-03-27
KR100310122B1 (ko) 2002-04-24
BG61611B1 (bg) 1998-01-30
EP1132404A2 (en) 2001-09-12
ATE204882T1 (de) 2001-09-15
CZ78996A3 (en) 1996-10-16
RU2164520C2 (ru) 2001-03-27
DE122004000035I1 (de) 2005-02-24
NO2004006I2 (no) 2008-02-04
DE69428134T2 (de) 2002-05-02
PT792290E (pt) 2002-01-30
CA2171424C (en) 2002-06-04
CN1133598A (zh) 1996-10-16
EP0792290B1 (en) 2001-08-29
WO1995007931A1 (en) 1995-03-23
US5750497A (en) 1998-05-12
NL300160I2 (nl) 2005-07-01
CN1056618C (zh) 2000-09-20
FI961220A0 (fi) 1996-03-15
IL110977A (en) 2000-06-29
HU217684B (hu) 2000-03-28
NO2004006I1 (no) 2004-10-11
IL110977A0 (en) 1994-11-28
NZ273285A (en) 1997-10-24
HUT75991A (en) 1997-05-28
JP3917333B2 (ja) 2007-05-23
JPH09502867A (ja) 1997-03-25
NO2017041I2 (no) 2018-11-19
FI961220A (fi) 1996-05-14
PL178466B1 (pl) 2000-05-31
BR9407508A (pt) 1997-01-07
FI117055B (fi) 2006-05-31
FR04C0020I2 (fr) 2005-05-27
AU682061B2 (en) 1997-09-18
SI0792290T1 (en) 2001-12-31
DE122004000035I2 (de) 2009-08-06
SK282495B6 (sk) 2002-02-05
EP0792290A1 (en) 1997-09-03
AU7652094A (en) 1995-04-03
NO2017041I1 (no) 2017-08-01
CA2171424A1 (en) 1995-03-23
UA45321C2 (uk) 2002-04-15
JP3014764B2 (ja) 2000-02-28
BG100420A (bg) 1996-12-31
FR04C0020I1 (no) 2004-10-29
PL313444A1 (en) 1996-07-08
JP4060583B2 (ja) 2008-03-12
AU4846197A (en) 1998-02-19
CZ287945B6 (cs) 2001-03-14
DK0792290T3 (da) 2001-10-01
LU91101I2 (en) 2004-11-08
DE69428134D1 (de) 2001-10-04
JP2002308899A (ja) 2002-10-23
RO112873B1 (ro) 1998-01-30
KR960704925A (ko) 1996-10-09
JP2000060556A (ja) 2000-02-29
NO961070L (no) 1996-05-15
ES2163451T3 (es) 2002-02-01

Similar Documents

Publication Publication Date Title
NO2017041I1 (no) Insulin detemir - forlenget SPC
RU96108249A (ru) Ацилированный инсулин
NZ330700A (en) B27, B28, B29 (B chain) insulin derivatives having a rapid onset of action
CA2081659A1 (en) Recombinant human factor viii derivatives
PH27425A (en) Insulin derivatives the use thereof and a pharmaceutical formulation containing them
KR900002801A (ko) 당뇨병 치료용 약학적제제
EP0105759A3 (en) Human pancreatic grf
PL322299A1 (en) Derivatives of insulin
KR920701250A (ko) 신규 인슐린 화합물
SG47913A1 (en) Substitution analogues of magainin peptides
EP0911035A3 (en) Insoluble insulin compositions
Marti et al. Hb Altdorf α2β2 135 (H13) Ala→ Pro: A new electrophoretically silent unstable haemoglobin variant from Switzerland
HU911358D0 (en) Grf analogues
GR3015492T3 (en) ZNS-active hexapeptides with antiamnestic activity.
DK119391A (da) Humaninsulinanaloger

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: LEVENMIR; NAT. REG. NO/DATE: EU/1/04/278/001-009/NO 20040614

Spc suppl protection certif: 2004006

Filing date: 20040927

Extension date: 20181110

ERR Erratum

Free format text: I PATENTTIDENDE NR.06/08 BLE DET I KUNNGJORINGEN AV MEDDELT SUPPLERENDE BESKYTTELSESSERTIFIKAT FOR LEGEMIDLER NR. 2004006, OPPGITT FEIL FORSTE MARKEDSFORINGSTILLATELSE I NORGE VED STATENS LEGEMIDDELVERK, RIKTIG SKAL VAERE:EU/1/04/278/001-009/NO, 20040601

MK1K Patent expired
SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: INSULIN DETEMIR; NAT. REG. NO/DATE: NO, EU/1/04/278/001-009 20040601; FIRST REG. NO/DATE: CH, 56370,71,72 20031110

Spc suppl protection certif: 2017041

Filing date: 20170801

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: INSULIN DETEMIR; NAT. REG. NO/DATE: NO, EU/1/04/278/001-009 20040601; FIRST REG. NO/DATE: CH, 56370,71,72 20031110

Spc suppl protection certif: 2017041

Filing date: 20170801

Extension date: 20190510

SPCX Expiry of an spc

Spc suppl protection certif: 2004006

SPCX Expiry of an spc

Spc suppl protection certif: 2017041